The startup develops a cell and gene therapy platform that utilizes M83-based CAR-T cells, which are engineered to resist exhaustion and enhance metabolism in the tumor microenvironment. This technology enables researchers to create more effective T cell-based therapeutics and gene therapies aimed at curing cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Current cell and gene therapies face challenges with T cell exhaustion and metabolic limitations within the tumor microenvironment, hindering their effectiveness in treating cancer. Engineering T cells to overcome these limitations is crucial for developing more potent and durable cancer therapies.
Solution
This startup is developing a cell and gene therapy platform leveraging M83-based CAR-T cells engineered for enhanced resistance to exhaustion and improved metabolism within the tumor microenvironment. By modifying T cells with the M83 technology, the platform aims to create more effective and persistent T cell-based therapeutics. This approach seeks to overcome the limitations of existing CAR-T cell therapies, leading to improved clinical outcomes and potentially curative treatments for various cancers. The enhanced metabolic fitness of the engineered T cells allows them to maintain their cytotoxic activity for longer periods within the harsh tumor environment.
Target Audience
The primary target audience includes researchers and pharmaceutical companies involved in developing cell and gene therapies for cancer treatment.
Features
- M83-based CAR-T cell engineering for enhanced resistance to T cell exhaustion
- Improved T cell metabolism within the tumor microenvironment
- Enhanced cytotoxic activity and persistence of engineered T cells
- Potential for curative treatments for various cancers